Company intelligence
Kazia Therapeutics Limited
Beyond Inhibition. Reprogramming Cancer Control.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA) is a clinical-stage oncology company focused on high-need cancers of the central nervous system and select aggressive solid tumors. Founded in 2016, the company is dedicated to advancing transformative therapies by harnessing next-generation science, disciplined development, and a commitment to clinical impact. Our mission is to redefine cancer treatment by moving beyond conventional pathway inhibition toward therapeutic reprogramming of cancer biology by targeting regulatory drivers of growth, immune escape, and relapse to deliver more durable outcomes for patients with the greatest unmet need.
Verified activity
Signals from Kazia Therapeutics Limited
6 published signals
Capital & Finance
Kazia Therapeutics Limited announced the oversubscribed closing of a public offering of up to $120 million, generating approximately $40 million in upfront gross proceeds.
Reported by Kazia Therapeutics Limited
Research & Knowledge
Kazia Therapeutics Limited is preparing to advance paxalisib into a Phase 2 clinical study in early 2027.
Reported by Kazia Therapeutics Limited
Research & Knowledge
Kazia Therapeutics Limited announced encouraging preclinical data for its lead asset paxalisib, demonstrating a 52% reduction in tumor burden in immunotherapy-resistant MSS/pMMR colorectal cancer as a monotherapy.
Reported by Kazia Therapeutics Limited
Research & Knowledge
Kazia Therapeutics Limited is expanding its three-arm trial to evaluate paxalisib in combination with fulvestrant, with and without palbociclib, against the standard of care, with first patient enrollment expected by year-end 2026.
Reported by Kazia Therapeutics Limited
Research & Knowledge
Kazia Therapeutics Limited expanded its breast cancer trial to include HR+/HER2- advanced breast cancer, representing an estimated 322,000 new U.S. diagnoses this year.
Reported by Kazia Therapeutics Limited
Legal & Regulatory
Kazia Therapeutics Limited filed a related provisional patent.
Reported by Kazia Therapeutics Limited